CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
1Title Page
Protocol Title: A Multicenter , Double- blind, Randomized, Placebo -controlled, Parallel- group 
Study  to Evaluate the Safety  and Ef ficacy  of MT10109L  (NivobotulinumtoxinA) for 
the 
Treatment of Glabellar Lines
Protocol Number: MT10109L -001
Amendment Number: Amendment [ADDRESS_779207]: MT10109L  (NivobotulinumtoxinA )
Brief Pr otocol Title: MT10109L  in the Treatment of Glabellar Lines
Development Phase: 3
Sponsor Name [CONTACT_29560]:
Allergan Sales LLC
 
Regulatory Agency Identifying Numbers: IND Number 121473;
EudraCT Number 2014-005300-16
Sponsor  Signatory:
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
2
Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment 4 September 2020
Amendment 3 February 2019
Amendment 2 November 2018
Amendment 1 September 2018
Original Protocol May 2018
Amendment 4 ( September  2020)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union
because it neither significantly  impacts the safety  or phy sical/mental integrity  of participants nor 
the scientific v alue of the study .
Overall Rationale for  the Amendment:
The overall rationale of this protocol amendment was to integrate feedback and 
recommendations from a health authorit y
.
Section No. and Nam e Description of Change Brief Rationale
Title Page Updated s ponsor signatory Administrative
 
11 References Added references References added to Section [IP_ADDRESS]
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779208] of Figures ................................................................................................................................ . 6
Protocol Summar y......................................................................................................... 7
Synopsis ........................................................................................................................... 7
Introduction .................................................................................................................. 14
Study  Rationale .............................................................................................................. 14
Background .................................................................................................................... 14
Benefit/Risk Assessment................................................................................................ 15
Objectives and Endpoints ............................................................................................ 17
Study Design ................................................................................................................. 19
Overall Design ............................................................................................................... 19
4.1.1 Clinical Hy potheses ....................................................................................................... 20
End of Study  Definition ................................................................................................ .21
Study Population .......................................................................................................... 22
Inclusion Criteria ........................................................................................................... 22
Exclusion Criteria .......................................................................................................... 23
Lifesty le Considerations ................................................................................................ 25
Screen Failures ............................................................................................................... 26
Study Intervention ....................................................................................................... 27
6.1.2 Instru ctions for Use and Administration ........................................................................ 28
Preparation/Handling/Storage/Accountability ............................................................... 29
Study  Intervention Compliance ..................................................................................... 31
Concomitant Therap y.................................................................................................... 31
6.5.3 Rescue Medicine ............................................................................................................ 32
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
4
Dose Modification ......................................................................................................... 32
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ....................................................................................... 34
Discontinuation of Study Intervention ........................................................................... 34
Participant Discontinuation/W ithdrawal from the Study ............................................... [ADDRESS_779209] to Follow Up .......................................................................................................... 35
Study Assessments and Pr ocedures ............................................................................ 36
Efficacy  Assessments ..................................................................................................... 36
8.1.1 Facial W rinkle Scale W ith Photonumeric Guide (FWS) ............................................... 36
 
Safety  Assessments ........................................................................................................ 38
8.2.1 Adverse Events .............................................................................................................. 38
8.2.2 Physical Examination ..................................................................................................... 38
8.2.4 Vital Signs ...................................................................................................................... 39
8.2.5 Electrocar diograms ........................................................................................................ 39
8.2.6 Hematology  and Blood Chemistry ................................................................................. 40
8.2.7 Urine Pregnancy  Tests ................................................................................................... 40
8.2.8 Suicidal Risk Monitoring ............................................................................................... 40
Adverse Events and Serious Adverse Events ................................................................ 40
8.3.1 Time Period and Frequency  for Collecting Adverse Event and Serious Adverse Event  
Information .................................................................................................................... 41
8.3.2 Method of Detecting Adverse Events and Serious Adverse Events .............................. 41
8.3.3 Follow -up of Adverse Events and Serious Adverse Events ........................................... 41
8.3.4 Regulatory  Reporting Requirements for Serious Adverse Events ................................ .42
8.3.5 Pregnancy ....................................................................................................................... 42
8.3.7 Medication Errors .......................................................................................................... 43
Treatment of Overdose .................................................................................................. 43
Pharmacokinetics ........................................................................................................... 44
Pharmaco dynamics ........................................................................................................ 44
Genetics ......................................................................................................................... 44
Medical Resource Utilization and Health Economics ................................................... 45
Statistical Considerations ............................................................................................ 46
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
5
Statistical Hy potheses .................................................................................................... 46
Sample Size Determination ........................................................................................... 47
Populations for Anal yses............................................................................................... 47
Statistical Analy ses........................................................................................................ 48
9.4.1 Efficacy  Analyses........................................................................................................... 48
[IP_ADDRESS] Primary  Efficacy  Endpoints ............................................................................... 48
[IP_ADDRESS] Primary  Analyses............................................................................................... 48
[IP_ADDRESS] Secondary  Efficacy  Endpoints ........................................................................... 50
[IP_ADDRESS] Secondary  Analyses........................................................................................... 51
[IP_ADDRESS] Exploratory  Efficacy  Endpoints ......................................................................... 52
[IP_ADDRESS] Exploratory  Efficacy  Analyses........................................................................... 52
9.4.2 Safety  Analyses.............................................................................................................. 52
[IP_ADDRESS] Adve rse Events .................................................................................................. 53
[IP_ADDRESS] Vital Signs .......................................................................................................... 53
[IP_ADDRESS] Electrocardiograms ............................................................................................ 54
9.4.3 Other Anal yses............................................................................................................... 54
[IP_ADDRESS] Immunogenicit y Anal yses.................................................................................. 54
Interim Anal yses............................................................................................................ 54
Supporting Documentation and Operational Considerations ................................ .55
Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................ 56
10.1.1 Regulatory  and Ethical Considerations .......................................................................... 56
10.1.2 Financial Disclosure ....................................................................................................... 56
10.1.3 Informed Consent Process ............................................................................................. 57
10.1.4 Data Protection ............................................................................................................... 57
10.1.5 Posting Clinical Study  Data ........................................................................................... 57
10.1.6 Data Qualit y Assurance .................................................................................................. 58
10.1.7 Source Documents ......................................................................................................... 58
10.1.8 Study and Site Closure ................................................................................................... 58
10.1.10 Compliance with Protocol .............................................................................................. 59
Appendix 2: Clinical L aboratory  Tests .......................................................................... 60
Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting .............................................................................................. 61
Definition of AE............................................................................................................................ 61
Definition of SAE ......................................................................................................................... 63
Recording and Follow -Up of AEs and/or SAEs ........................................................................... 64
Reporting of SAEs ........................................................................................................................ 66
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
6
Appendix 4: Abbreviations ............................................................................................ 67
Appendix 10: Protocol Amendment History ................................................................ .[ADDRESS_779210] of Figur es
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
7
Protocol Summary
Synopsis
Protocol Title : A Multicenter , Double -blind, Randomized, Placebo -controlled, Parallel -group 
Study  to Evaluate the Safety  and Ef ficacy  of MT10109L  (NivobotulinumtoxinA) for the 
Treatment of Glabellar Lines
Protocol Number:  MT10109L -001
Brief Title: MT10109L  in the Treatment of Glabellar L ines
Study Phase : 3
Study Rationale :
The purpose of this placebo- controlled pi[INVESTIGATOR_591109]10109L  for the treatment of glabellar lines (GL) in participants  with moderate to severe GL  
.
Objectives and Endpoints:
Objec tives Endpoints
Primary
To compare the efficacy between
20UMT10109L and placebo for 
the tr eatment of GL in participants 
with moderate to severe GLFor US FDA:
 Com posite: The p roportion of participant s with a ≥ 2-grade 
improvement from baseline on the Facial Wrinkle Scale With 
Photonumeric Guide (FWS )according to investigator and 
participant assessments of GL severity at maximum frown at Day 30
using the intent -to-treat (ITT) population after a single 
intramuscular (IM) injection of MT10109L or placebo in the GL
For EU regulatory agencies:
  
 
Secondary
To compare the efficacy between 
MT10109L and placebo for the 
treatment of GL in participants 
with moderate to severe GL
To compare the safety between 
MT10109L and placebo for the 
treatment of GL in participants 
with moderate to severe GLFor US FDA:
 Secondary: The duration of GL treatment effect, estimated as the 
median time to return to moderate or severe GL at maximum frown, 
in participants who achieved a rating of ≥ 2-grade improvement 
from baseline in GL severity at maximum frown at Day 30 
accordi ng to investigator assessments using the FWS
 Secondary: The proportion of responders for investigator 
assessments of GL severity at maximum frown using the FWS, 
where a responder is defined as achieving a ≥ 2-grade improvement 
from baseline at maximum frow n at Day 30
  
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
8
 Secondary: The proportion of parti cipants reporting mostly 
satisfied /very satisfied on the Facial Line Satisfaction Questionnaire
(FLSQ) follow -up version Item 5 for GL at Day 60
 Secondary: The proportion of responders for investigator 
assessments of GL severity at rest using the FWS among 
participants who were rated at least mild at rest at baseline, where a 
responder is defined as achieving a ≥ 1-grade improvement from 
baseline a t Day 30
 Secondary: Incidence of adverse events; change from baseline in 
vital sign and electrocardiogram ( ECG )param eters; and presence of 
binding and neutralizing antibodies
For EU regulatory agencies:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
9Overall Study Design:
This is a multicenter, randomized, double -blind, placebo -controlled, parallel -group 
Phase 3 study  to evaluate the safet y and efficacy of MT10109L  in treating GL . 
 
Participants are adults ≥ 18 y ears of age with moderate to severe GL at maximum frown 
(assessed b y both the investigator and participant using the FWS [investigator and 
participant ratings must be the same for GL ]).
The primary  efficacy  measure is the investigators’ and participants’ assessments of GL at 
maximum frown using the FWS, and the primary  timepoint is Day  [ADDRESS_779211] 
intervention.
Participants will attend a Screening Visit up to 28 days before enrollment on Day  1.  
 
 
 
 
The first treatment period (Day  1 with follow -up to Day  180) is a double -blind, 
randomized, placebo -controlled, parallel -
group, single treatment administration with a 
6-month follow - up.
On Day  1, participants will be randomly  assigned in a 2:1 ratio to receive 
MT10109L 20U or placebo.  
 
 
 
 
Participants who complete the study  will have an exit visit at Day  360.
 
Number  of Participant s:
Approximately  [ADDRESS_779212] approximately  190 participants 
complete th e study  
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
10Number  of Sites :
Approximately  16 global sites
Intervention Gr oups and Study Duration:
The total duration of study  participation for each participant is approximately  12 months 
(Day 1 randomization/treatment to end of study /Day  360). Participants will attend the 
following visits:
oScreening (up to 28 day s prior to Day  1)
oRandomization and treatment (Day  1)
oFollow -up visits on Day s 7 and 14 after each intervention
oMonthly  (Day s 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, and 330)
oExit (Day  360 [ completion ] or early  exit)
On Day  1, participant s will receive IM injections of MT10109L  20U or placebo.
During the retreatment period (Day  180 through Day  330), participants who meet 
retreatment criteria will receive up to [ADDRESS_779213] an exit visit at Day  360.
Data Monitoring Committee:  No
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
11
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
12
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
13
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
14
Introduction
Study Rationale
The purpose of this placebo- controlled, pi[INVESTIGATOR_591110]10109L  for the treatment of GL  in participants with moderate to severe GL   
Back ground
 
 
 
 
 
Glabellar lines are deep furrows or frown lines in the glabellar area of the face, and LCL  (or 
CFL) are horizontal smile  lines by [CONTACT_591112]. Both t ypes of facial lines result from the 
repetitive functional action of the underl ying mimetic facial musculature during animation 
(Blitzer 1993). When injected at therapeutic doses, MT10109L  produces partial chemical 
denervation of the muscle, resulting in localized reduction in muscle activity . Beca use GL  and 
LCL result from muscular activity , the muscle relaxation leads to a temporary  relief of facial 
lines. While it was previously  thought that these facial lines were structural and permanent, the 
effects of these injections demonstrate the lines are part functional and remain because of 
constant muscle tone ( Ferreira 2004 ; Garcia 1996).
The development of facial lines (such as GL  and LCL) is an age -related change of the face that 
occurs bec ause of the repetitive muscle contractions that are associated with common facial 
expressions. Thus, these facial lines can be observed with contraction (d ynamic rh ytides) or in 
more severe cases in repose (static rh ytides). Increasing severit y in the appe arance of facial lines 
has been associated with a patient ’s perception of reduced attractiveness and a negative ef fect on 
self-esteem and sense of well -being ( Koblenzer 1996 ). Furthermore, the appearance of these 
facial lines can lead to a miscommunication of an emotional state of anger , anxiety , disapproval, 
or sadness ( Khan 2001) causing distress and affecting social interactions ( Finn 200 3).
Evidence supports that unattractive or aging skin is indeed related to psy chological and 
psychosocial impacts ( Farage 2010).  
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
15The popularit y of BoNT /A cosmetic treatment of GL and LCL  in adults is related to its proven 
efficac y for reducing moderate to severe facial lines  (Beer 2006 ); well documented safet y profi le 
(Brin 2009); and positive impact on psy chological well- being and the resulting ps ychosocial 
benefits ( Finn 2003 ).
Benefit/Risk  Assessment
Generally , the popularit y of BoNT/A  cosmetic treatment of GL and LCL  in adults is related to its 
proven ef ficacy for reducing moderate to severe facial lines ( Beer 2006 ); well documented safet y 
profile  (Brin 2009); and positive impact on psy chological well -being and the resulting 
psychosocial benefits ( Finn 2003).  Compared with the general class of BoNT/A  treatme nts, 
MT10109L  provides additional benefits. For one, i t is provided as a read y-to-use liquid product . 
Secondly , it is manufactured without  human- or  animal- derived products . MT10109L  also of fers 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
16
potential ef ficacy  and safety  advantages in addition to convenience since it does not require 
reconstitution and has shown sustained benefit in the treatment of GL.  
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
17
Objectives and Endpoints
Objectives Endpoints
Primary
To compare the efficacy between
20UMT10109L and placebo for the 
treatment of GL in participants with 
moderate to severe GLFor US FDA:
 Com posite: The p roportion of participant s with a ≥ 2-grade 
improvement from baseline on the FWS according to 
investigator and participant assessments of GL severity at 
maximum frown at Day 30using the ITT population after a 
single IM injection of MT10109L or placebo in the GL
For EU regulatory agencies:
 Coprimary: The proportion of participants achieving a rating of 
 
 
Secondary
To compare the efficacy between 
MT10109L and placebo for the 
treatment of GL in participants with 
moderate to severe GL
To compare the safety between 
MT10109L and placebo for the 
treatment of GL in participants with 
moderate to severe GLFor US FDA:
 Secondary: The duration of GL treatment effect, est imated as the 
median time to return to moderate or severe GL at maximum 
frown, in participants who achieved a rating of ≥ 2-grade 
improvement from baseline in GL severity at maximum frown at 
Day 30 according to investigator assessments using the FWS
 Second ary: The proportion of responders for investigator 
assessments of GL severity at maximum frown using the FWS, 
where a responder is defined as achieving a ≥ 2-grade 
improvement from baseline at maximum frown at Day 30
  
 
 
 Secondary: The proportion of participants repo rting mostly 
satisfied /very satisfied on the FLSQ follow -up version Item 5 for 
GL at Day 60
 Secondary: The proportion of responders for investigator 
assessments of GL severity at rest using the FWS among 
participants who were rated at least mild at rest at baseline, 
where a responder is defined as achieving a ≥ 1-grade 
improvement from baseline at Day 30
 Secondary: Incidence of adverse events; change from baseline in 
vital sign and ECG parameters; and presence of binding and 
neutralizing antibodies
For EU r egulatory agencies:
  
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
18
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
19
Study Design
Overall Design
This is a multicenter, randomized, double -blind, placebo -controlled, parallel- group 
Phase 3 study  conducted across approximately  16 global sites to evaluate the safet y and 
efficacy  of MT10109L in treating GL. Participants may  receive up to 3 study  
interventions (a single double -blind intervention of MT10109L  20U or placebo and up to 
2 open- label interventions with MT10109L  20U). 
Participants are adults ≥ 18 y ears of age with moderate to severe GL at maximum frown 
(assessed b y both the investigator and participant using the FWS [investigator and 
participant ratings must be the same for GL ]).
The primary  efficacy  measure is the investigators’ and participants’ assessments of GL 
severit y at maximum frown using the FWS, and the primary timepoint is Day [ADDRESS_779214] intervention.
Participants will attend a Screening Visit up to 28 day s before enrollment on Day  1.  
The first treatment period (Day  [ADDRESS_779215] Day  180) is a double -blind, 
randomized, placebo- controlled, parallel -group, single treatment administration with a 
6-month follow -up.
On Day  1, participants will be randomly  assigned in a 2:1 ratio to receive 
MT10109L 20U or placebo.  
 
 
 
 
MT10109L  20U or placebo will be administered as 5 IM injections: 5 to the GL complex 
(2 in each corrugator muscle, 1 in the procerus muscle), 0.1 mL (4U MT10109L  or 0 U 
placebo) per injection.
 
 
 
 
Participants who complete the study  will have an exit visit at Day  360.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
20The total duration of study  participation for each participan t is approximately  12 months 
(Day 1 randomization/treatment to end of study /Day  360). Participants will attend the 
following visits:
oScreening (up to 28 day s prior to Day  1)
oRandomization and treatment (Day  1)
oFollow -up visits on Day s 7 and 14 after each i ntervention
oMonthly  (Day s 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, and 330)
oExit (Day  360 [comp letion] or early  exit)
 
Approximately  [ADDRESS_779216] approximately  190 participants complete the study   
 
Participants who prematurely  discontinue from the study  will not be replaced.
4.1.1 Clinical Hypotheses
MT10109L  20U is mo re effective than placebo in treating GL, measured by  [CONTACT_141171]’ 
and participa nts’ assessments of GL  severit y at maximum fr own using the FWS.
MT10109L  20U has an acceptable safet y profile after single and repeat treatments.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779217] completed the study  if he/she has completed all phases of the 
study  including the last scheduled procedure shown in the SoA.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779218] y:
1. Age
1.[ADDRESS_779219] be ≥18 years of age and considered to be an adult in her/his local 
jurisdiction at the time of signing the informed consent .
2. Type of Participant  and Characteristics
2.01 Moderate to severe GL at maximum frown (as assessed by [CONTACT_591113]; ) using the FWS
2.[ADDRESS_779220] sufficient visual acuit y without the use of ey eglasses (contact 
[CONTACT_591114]) to accuratel y assess their GL lines, in the opi[INVESTIGATOR_1070].
3. Sex
3.[ADDRESS_779221] before each stud y intervention. A female is conside red NOT  to be of 
childbearing potential if she is premenarch al, postmenopausal (at least 
12consecutive months without menstruation), or permanentl y sterilized (eg, tubal 
occlusion, hy sterectom y, bilateral oophorectomy ).
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
235. Informed Consent
5.01 Capable of giving signed informed consent as described in Appendix 1,which 
includes compliance with the requirements and restrictions listed in the ICF and in 
this protocol
5.02 Written informed consent from the participant has been obtained prior to any study-
related procedures.
Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
1. Medical Conditions
1.01 Any condition which precludes a participant’s ability  to comply  with study requirements, 
including completion of the study visits or inability to read, understand, and/or self -assess 
GL severit y using the FWS
1.03 Any medical condition that may put the participant at increased risk with exposure to 
MT10109L  including diagnosed myasthenia gravis, Eaton -Lambert syndrome, 
amyotrophic lateral sclerosis, or any other condition that might interfere with 
neuromuscular function
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
24 
 
1.09 Any uncontrolled s ystemic disease
1.11 Anticipated need for treatment with botulinum toxin of an y serotype for an y reason during 
the study  (other than study  intervention)
1.12 Anticipated need for surgery  or overnight hospi[INVESTIGATOR_16366]
2. Prior/Concomitant Therapy/Pr ocedur es
2.01 Prior exposure to botulinum toxin of any  seroty pe for any  reason
 
 
 
 
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
25
2.06 Prior facial treatment with permanent soft tissue fillers, synthetic implantation 
(eg,Gore -Tex®), and/or autologous fat transplantation
3. Prior/Concurrent Clinical Study Experience
3.[ADDRESS_779222]  from the immediate area of the stud y 
site that would preclude them from returning for all protocol specified stud y visits
 
 
 
 
 
 
 
 
 
 
 
Lifestyle Considerations
No restrictions are required.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
26
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently  entered in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the CONSOR T publishing 
requirements and to respond to queries from health  authorities. Minimal information includes 
demographics , screen fa ilure details, eligibility  criteria, and an y SAE .
Screen failures can occur during the screening period  up to the Day  1 Visit.  
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
27
Study Intervention
Study  intervention is defined as an y investigational intervention(s), marketed product(s), or 
placebo intended to be administered to a study  participant according to the study  protocol.
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
28
 
 
 
 
 
 
6.1.2 Instructions for Use and Administration
Only trained and medically  qualified ph ysicians experienced with BoNT/A  injections are 
authorized to administer the study intervent ions. Study -specific training for GL  injections are 
provided to investigators  
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779223]  be observed for adverse events for ≥ 30minutes after each study  intervention.
 
 
 
 
Preparation/Handling/Storage /Accountability
1.The investigator or designee  must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and an y discrepancies are 
reported and resolved before  use of the stud y intervention.
2.Only  participants enr olled in the study  may  receive study  intervention, and only  authorized 
site personnel  may  administer study  intervention. All study  intervention must be stored in a 
secure , environmentall y controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
personnel .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
303.The investigator , institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconci liation, and record maintenance (ie , 
receipt, reconciliation , and final disposition records) .
4.Further guidance and information for the final disposition of unused study  interventions are 
provided in the study  manual.
All unused study  intervention and empty  vials  must be returned to the sponsor at the termination 
of the study . Unit counts will be performed when the study  intervention is returned, and all study  
intervention must be accounted for . Unused drug  supplies and empty  vials  will be returned to the 
sponsor .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779224] that specifies the a mount of study  
intervention administered to each participant and the date of administration.
Concomitant Therapy
The use of an y concomitant medication or vaccine (including prescription or over -the-counter 
medication, vitamins, and/or herbal supplements) i s to be recorded on the participant ’s eCRF at 
each visit along with the reason the medication is taken.
At screening and end of study  and upon admission to and discharge from the study site , study  
site personnel will question each participant  specifically  on the use of concomitant medications. 
Study  site personnel must notify  the s ponsor immediatel y if a participant  consumes any  
concomitant medications not permitted by  [CONTACT_760]. Participants  who admit to using 
prohibited concomitant medica tions may  be discontinued from the study  at the discretion of the 
investigator or the sponsor .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
326.5.3 Rescue Medicine
Rescue medicine is not applicable.
Dose Modification
This protocol does not  allow for alteration from the current ly outlined dosing schedule.
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
33
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
34
Discontinuation of Study Intervention and Participant 
Discontinuation/ Withdrawal
A premature discontinuation will occur if a participant who signs the ICF and is randomized 
ceases participation in the study , regardless of circumstances, before the completion of the 
protocol -defined stud y procedures.
Notification of early  participant discontinuation from the study  and the reason for 
discontinuation will be made to the sponsor and will be clearl y document ed on the 
appropriate eCRF.
Reasons for discontinuation from the study  intervention and/or the study  may  include the 
following commonl y used terms:
Comm only Used T erms
Adverse event
Lost to follow -up
Lack of efficacy
Other
Physician decision
Pregnancy
Protocol deviation
Site terminated by [CONTACT_591115]:
Pregnancy  
Other safety  criteria  
Women who test positive for urine pregnancy  test will NOT  receive further treatment and will be 
discontinued from  the study . They  should compl ete study  exit procedures and be followed up for 
pregnancy outcome. See the SoA  for data to be collected at the time of intervention 
discontinuation and follow -up and for an y further evaluations that need to be completed.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
35
Participant Discontinuation/W ithdrawal  from the Study
A participant may  withdraw from the stud y at an y time at his/her own request, or may be 
withdrawn at an y time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons.
If the participant withdraws consent for disclosure of future information, the sponsor may  
retain and continue to use an y data collected before such a withdrawal of consent.
See the SoA for data to be collected at the time of study  discontinuation and follow -up 
and for an y further evaluations that need to be completed.
Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following a ctions must be taken if  a participant fails to return to the study  site for a required 
study  visit:
The study  site must attempt to contact [CONTACT_288949]/or 
should continue in the study .
Before a participant is deemed lost to follow -up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_9145]’s 
medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
36
Study Assessme nts and Procedures
Study  procedures and their timing are summarized in the SoA.  
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the part icipant should continue or discontinue 
study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm th at potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
 
 
Efficacy Assessments
8.1.1 Facial Wrinkle Scale With Photonumeric Guide (FWS)
Investigator s’ and participants ’ assessments of the severit y of G L at rest and maximum frown 
using  the validated FWS , based on the following scale:
0 = None
1 = Mild
2 = Moderate
3 = Severe
 
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
37
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
38
Safety Assessments
Planned timepoints for all safet y assessments are provided in the SoA .
8.2.1 Adverse Events
The investigator will question the participant to ascertain whether an y adverse events were 
experienced since the previous visit . Additionally , at treatment visits, the participants will be 
observed for ≥ 30 minutes following stud y intervention. All pertinent  information regarding 
adverse events (ie, date of onset and stop, duration, outcome, severity , relationship to study  
intervention, action or treatment required) will be obtained and recorded in the source documents 
and appropriate eCRF page.
8.2.2 Physical Examination
Physical examination will be conduc ted at the Screening Visit  
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
39 
 
8.2.4 Vital Signs
Pulse rate (beats per minu te): Participa ntsare to be seated for at least 2 minutes, and pulse rate 
will be counted over 60 seconds, and recorded in the source document and eCRF as beats per 
minute.
Blood pressure (mm Hg): Participa ntsare to be seated for at least 2 minutes, and 
systolic/diastolic blood pressure will be measured.
Respi[INVESTIGATOR_1487] (breaths per minute): Participa ntsare to be seated for at least 2 minutes, and 
breaths will be counted for 30 seconds and multiplied by 2.
8.2.5 Electrocardiograms
All participants will undergo conventional [ADDRESS_779225] 10 minutes prior to starting the tracing. During screening, 
a single ECG trace will be taken to assess entry  eligibility .
A qualified third -party vendor will read the ECGs and report the findings as normal, 
abnormal, or unable to evaluate.
 
 
 
 
 
 
 
 
 
 
The ECG will be assessed for the following measures: heart rate, QRS duration , QT interval, 
QTcB interval, QT cF interval, ST  segment, RR interval, PR interva l, and qualitative results.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
408.2.6 Hematology and Blood Chemistry
See Appendix [ADDRESS_779226] of clinical laboratory tests to be performed and the SoA  for the 
timing and frequency .
Hematology  and nonfasting blood chemistry  assays will be performed b y a central 
laboratory .
During the Screening Period, the investigator or subinvestigator will assess the clinical 
significance of an y values outside the reference ranges provided b y the laboratory , and 
participants with abnormali ties judged to be clinically  significant will be excluded from the 
study .
8.2.[ADDRESS_779227] pregnancy tests at the timepoints specified in the SoA, 
or more frequently , at the investigator ’s discretion.
8.2.8 Suicid al Risk Monitoring
Suicidal risk monitoring is not applicable  for this study .
Adverse Events  and Serious Adverse Events
The definitions of an adverse event  or SAE can be found in Appendix 3.
Adverse event s will be reported by  [CONTACT_2299].
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an adverse event  or SAE and remain responsible for 
following up adverse events that are s erious, considered related to the stud y intervention or study 
procedures, or that caused the participant to discontinue the study  intervention (see Section 7).
Adverse drug reactions for MT10109 L have not been established.  
The following expected adverse drug reactions are based on BOTOX clinical trial data for the 
treatment of GL  (Table8-1).
Table 8-1 Expected Adverse Reactions for Treatm ent of Glabellar Lines
Expected Adverse ReactionsaIncidence
Eyelid ptosis 3%
Facial pain 1%
Facial paresis 1%
Muscular weakness 1%
a Data are based on BOTOX glabellar lines  clinical trial data  (BOTOX Cosmetic US Package Insert, 2017 )
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779228] administration of study  
intervention will be collected at the timepoints specified in the SoA (Section 1.3), and as 
observed or reported spontaneously  by [CONTACT_171579] .
All SAEs will be recorded and reported to the sponsor or designee within 24 hours, as indicated 
in Appendix 3 . The investigator will submit any  updated SAE data to the sponsor within 
24hours of 
it being available.
Investigators are not obligated to activel y seek adverse event or SAE information after 
conclusion of the study  participation. However , if the investigator learns of any  SAE, including a 
death, at an y time after a participant has been di scharged from the study, and he/she considers the 
event to be reasonabl y related to the study  intervention or study  participation, the investigator 
must promptly  notify  the sponsor .
The method of recording, evaluating, and assessing causality  of adverse ev ents and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
8.3.2 Method of Detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting 
adverse event s and/or SAEs. Open- ended 
and nonleading verbal questioning of the participant is the preferred method to inquire about 
adverse event occurrences.
8.3.3 Follow -up of Adverse Events and Serious Adverse Events
After the initial adverse event/SAE report, the investigator is required to proactivel y follow each 
participant who received study  intervention at subsequent visits/contacts. All TEAEs /SAEs , 
including AESI s  will be followed until resolution, stabiliz ation, the event is 
otherwise explained, or the participant is lost to follow -up .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779229] of supplemental 
measurements and/or evaluations as medically  indicated or as requested by [CONTACT_325740]/or causalit y of the adverse event or SAE as fully  as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
If a participant dies during participa tion in the study  or during a recognized follow -up period, the 
investigator will provide the sponsor with a cop y of an y postmortem findings including 
histopathology .
New or updated information will be recorded in the originally  completed eCRF .
The investig ator will submit any  updated SAE data to the sponsor within 24 hours of receipt of 
the information.
8.3.4 Regulatory Reporting Requirements for Serious Adverse Events
Prompt notification by  [CONTACT_19990] y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ IECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary  or listing of SAEs) from the sponsor will review 
and then file it along with the investigator ’s brochure and will notify  the IRB/IEC, if 
appropriate according to local requirements.
8.3.5 Pregnancy
Urine pregnancy  testing will be conducted for women of childbearing potential prior to each 
study  intervention, and at the study  exit visit. See Appendix 7 for detailed information on 
definition of women of childbearing potential, use of contraceptives, and pregnancy .
To minimize the risk of pregnancy , all women of childbearing potential must agree to use a 
highl y effective or acceptable contraception method ( Appendix 7 ) consistently  and correctly  
throughout t he duration of the study . 
Women who test positive for urine pregnancy  test will NOT receive further treatment and 
will be discontinued from the study .
Women who test positive for urine pregnancy  test should complete end -of-study  procedures 
and be followed up for pregnancy  outcome.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
43Any termination of pregnancy  will be reported, regardless of fetal status (presence or absence 
of anomalies) or indication for the procedure.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 7 .
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) or genetic abnormalities (whether leading to an elective 
abortion or not) are considered SAEs.
 
8.3.7 Medication Errors
Medication error refers to any  unintended error in  the dosing and/or administration of the study  
intervention as per instructions in the protocol. Medication  errors generall y fall into 4 categories 
as follows:
Wrong study  intervention
Wrong dose (including dosing regimen, strength, form, concentration, am ount)
Wrong route of administration
Wrong participant (ie, not administered to the intended participant)
Medication errors include occurrences of overdose and underdose of the study  intervention.
Overdose: Unintentional administration of a quantity  of the study  intervention given per 
administration that is above the maximum recommended dose according to the protocol for the 
study  intervention or comparator as applicable. See Section 8.4 for information on the treatment 
of overdose.
Underdose: Unintentional administration of a quantity  of the study  intervention given per 
administration that is under the minimum recommended dose according to the  protocol.
Treatment of O verdose
Overdose of MT10109L  is a relative term and depends upon dose, site of injection, and 
underly ing tissue properties. Signs and s ymptoms of overdose are  likel y not to be apparent 
immediately  postinjection. Excessive doses may  produce local , or distan t, generalized and 
profound neuromuscular paral ysis.
Because MT10109 L is administered as injections by  [CONTACT_13922], for this study , the chance of 
overdose is extremel y low . Should accidental injection or oral ingestion occur or overdose be 
suspected, the participant should be medically monitored for up to several weeks for progressive 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779230]. Supportive care could involve the need for a tracheostomy  and/or prolonged mechanical 
ventilation, in addition to other general supportive care .
In the event of an overdose , the investigator should  educate the participant, monitor the course of 
overdose, contact [CONTACT_591116] y physician as needed, document the quantity  of the excess 
dose, associated adverse events  as well as the duration of t he overdose in the eCRF .
Pharmacok inetics
Pharmacokinetic  parameters are not evaluated in this study .
Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
Genetics
Genetics are not evaluated in this study .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
45
Medical Resource Utilization and Health Economics
Medical resource utilization and health economics  parameters are not evaluated in this study .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
46
Statistical Considerations
Statistical Hypotheses
For US FDA:
The primary  efficacy  analy sis will be performed on the ITT  population, which consists of all 
randomized participants . The following h ypotheses will be used to compare MT10109L  20U 
with placebo:
Null hy pothesis: MT10109L  20 U and placebo are equall y effective in reducing GL severity 
at maximum frown as measured b y the proportion of responders with a ≥ 2-grade 
improvement from baseline based on both the investigator -and participant -rated FWS at 
Day 30.
Alternative h ypothesis: MT10109L  20 U and placebo are not equall y effective in reducing 
GL severit y at maximum frown as measured b y the proportion of responders with a 
≥ 2-grade improvement from baseline based on both the investigator -and participant -rated 
FWS at Day  30.
For EU r egulatory agencies:
 
 
 
 
 
 
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
47
Sample Size Determination
Approximately  225 participa nts will be randomized into the study  in a 2:[ADDRESS_779231] 1  injection of study  intervention. All safet y anal yses will be performed with 
participants anal yzed by [CONTACT_591117].
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779232] oratory  endpoints.
9.4.1 Efficacy Analyses
[IP_ADDRESS] Primary Efficacy Endpoints
For the US FDA, t he composite  efficac y endpoint s are the proportion of participant s with a 
≥ 2-grade improvement from baseline on the FWS according to both investigator and participant  
assessments of GL  severity  at maximum frown at Day 30 using the ITT  population  after a single 
IM injection of MT10109L  or placebo in the  GL.
 
[IP_ADDRESS] Primary Analyses
The primary  efficacy  analysis will be based on the comparison of GL  efficacy for MT10109L  
20U versus placebo at the primary  timepoint of Day [ADDRESS_779233] stratified 
by [CONTACT_1697] -assessed baseline GL  severit y at maximum frown. Relative risk and 95% CI for 
relative risk will be presented. Missing values will be imputed up to Day 180 using multiple 
imputation methods. SAS Proc MI  procedure will be used  
Seed for all Proc M I procedure is prespecified as .  
 
 
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
49 
 
 
 
 
 
 
 
 
  
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779234] treatme nt period.
Sensitivity  analy ses of the primary  efficacy  variables will be performed to establish their 
consistency  and robustness as well as to further characterize the extent of participants ’ responses . 
 
[IP_ADDRESS] Secondary Efficacy Endpoints
For US FDA:
The duration of GL treatment effect estimated as the median time to return to moderate or 
severe GL at maximum frown, in participants who achieved a rating of ≥
2-grade 
improvement from baseline in GL  severity  at maximum frown at Day  30 according to 
investigator assessments using the FWS.
The proportion of responders for investigator assessment s of GL  severit y at maximum frown 
using the FWS, where a responder is defined as achieving a ≥ 2- grade improvement from 
baseline at maximum frown at Day  30
 
 
The proportion of participants reporting mostly satisfied /very satisfied on the FLSQ 
follow -up version Item 5 for GL at Day 60.
The proportion of responders for investigator assessments of GL  severit y at rest using the 
FWS, among participants who were rated at least mild at rest at baseline, where a responder 
is defined as achieving a ≥ 1-grade improvement from baseline at Day  30.
For EU r egulatory agencies:
 
 
 
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
[IP_ADDRESS] Secondary Analyses
All secondary  variables will be evaluated for all study  visits with the prespecified primary  
timepoint given above , except for duration of treatment ef fect. The duration of GL  treatment 
effect is defined as the time to return to moderate or severe GL  at maximum frown, in those 
participant s achieving a responder 
status (for US FDA, responder is defined as participants who 
achieved a rating of ≥ 2-grade improvement from baseline in GL  severit y at maximum frown ; 
 
at Day  [ADDRESS_779235] stratified by  [CONTACT_591118] b y the clinician (investigator or subinvestigator) . The 
continuous variables and ordinal variables will be anal yzed using ANCOV A  
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
[IP_ADDRESS] Exploratory Efficacy Endpoints
For both the US FDA  and EU, anal yses for exploratory efficacy  endpoints will be performed on 
the ITT population.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS] Exploratory Effi cacy Analyses
The proportion of responders will be anal yzed using the CMH test  
9.4.2 Safety Analyses
The safet y analysis will be performed using th e safety  population and arefully  defined in the 
SAP. The safet y parameters will include:
Adverse events
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
53
Vital signs
Electrocardiogram
Immunogenicit y analyses
[IP_ADDRESS] Adverse Events
An adverse event will be considered a TEAE if:
The adverse event began on or after the date of the first dose of study  intervention; or
The adverse event was present before the date of the first dose of stud y intervention, but 
increased in severit y or became serious on or after the date of the first dose of study  
intervention
An adverse event that occurs more than [ADDRESS_779236] will be tab ulated by  [CONTACT_591119] .  
 
Summary  tables will be provided for participants with SAEs and participants with 
adverse event s 
leading to discontinuation if 5 or more participants reported such events. Listings of all adverse 
event s, SAEs, and adverse event s leading to discontinuation by  [CONTACT_217664].
The definitions of an adverse 
event and SAE can be found in Appendix 3 .
[IP_ADDRESS] V ital Signs
Descriptive summaries (n, mean, SD, median, minimum, and maximum) of actual values and 
changes from baseline will be calculated for vital signs (s ystolic and diastolic blood pressure, 
pulse and respi[INVESTIGATOR_1487] ). These summaries will be presented b y study intervention and b y visit.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
54
[IP_ADDRESS] Electrocardiograms
Descriptive statistics for ECG parameters (eg, heart rate, QRS duration, QT interval, QT c 
intervals , RR interval, and PR interval) at baseline, and changes from baseline at all postbaseline 
timepoints will be presented by  [CONTACT_268336]. For each parameter , only 
participant s who had both baseline postbaseline  assessments wi ll be included in the summary . 
 
 
9.4.3 Other Analyses 
[IP_ADDRESS] Immunogenicity Analyses
Immunogenicit y results, manifested as the presence of binding antibodies and neutralizing 
antibodies  to MT10109L, will be summarized in a table .
Interim Analyses
No interim anal ysis is planned.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
55
Supporting Documentation and Operational Considerations
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
56
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wi th the protocol and with the following:
oConsensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines
oApplic able ICH/ISO GCP guidelines
oApplicable laws and regulations
The protocol, protocol amendments, I CF, investigator’s brochure, and other relevant 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_31846]/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study  participants. 
The investigator will be responsible for the following:
oProviding written summaries of the status of the study  to the IRB/IEC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC
oNotify ing the IRB /IEC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
oProviding oversight of the overall conduct of the study  at the site and adherence to 
requirements of applicable local regulations, for example 21 CFR, I CH guidelines, the 
IRB/IEC, and European regulation 536/2014 for clinical studies (if applicable)
10.1.2 Financial Disclosure
Investigators and subinvestigators will provide the sponsor with suf ficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators are 
responsible for providing information on financial interests during the course of the stud y and for 
1 year after completion of th e study .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
5710.1.3 Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed th at their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements, where applicable, and the IRB/IEC 
or study  center.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the IC F.
Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study .
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative.
Participants who are res creened are required to sign a new ICF .
10.1.4 Data Protection
Participants will be assigned a unique identifier. Any  participant records or datasets that are 
transferred to the sponsor will contain the identifier only ; participant names or any  
information which would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explai ned to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_591120], by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory  authorities.
10.1.5 Posting Clinical Study Data
  
 
Clinical study  reports, safety  updates, and annual reports will be provided to regulatory  
authorities as required.
Company -sponsored study  information and tabular study  results will be posted on the US 
National Institutes of Health’s website www.ClinicalTrials.gov and other publicly  
accessible sites.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
5810.1.6 Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or eCRFs unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_55896] y or 
electronically  signing the eCRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agenc y inspections and provide direct access to source data documents.
The sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently approved protocol and any other stud y 
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  must 
be retained b y the investigator as stated in the clinical tri al agreement . No records may be 
destroy ed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party  without written notification to the sponsor.
10.1.7 Source Documents
Source documents pro vide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study .
Definition of what constitutes source data can be found in Section 4. 0 of I CH E6, Good 
Clinical Practice: Consolidated Guidance and must follow AL COA, ie, records must be 
attributable, legible, contemporaneous, original, and accurate.
10.1.[ADDRESS_779237] been collected and a study -site cl osure visit has been performed .
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
59
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and suf ficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the spo nsor or investigator may  include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IRB/IEC or 
local health authorities, the sponsor’s procedures, or GCP guidelines
Inadequate recruitment of participants b y the investigator
Discontinuation of further study  intervention development
10.1.[ADDRESS_779238] with the 
investigator and his/her research staff and will conduct regular monitoring visits at the site to 
review participan tand study  intervention accountability  records for c ompliance with the 
protocol. P rotocol deviations will be discussed with the investigator upon identification. The use 
of the data collected for the participan t will be discussed to determine if the data are to be 
included in the anal ysis. The investigator will enter data that may  be excluded from analy sis as 
defined b y the protocol deviation specifications. Significant protocol deviations will be reported 
to the I RB/IEC according to the IRB/ IEC’s reporting requirements.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
60
Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 10-1 will be performed by  [CONTACT_2237] .
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the stud y as determined necessary b y 
the investig ator or required by  [CONTACT_427].
Table 10-1 Protocol -required Safety Laboratory Assessments
Laboratory 
AssessmentsParam eters
Hem atology Platelets
RBC count
Hem oglobin
Hem atocrit
RBC morphologyWBC count with differential (absolute) :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Clinical 
ChemistryBUN
Potassium
AST
Total, direct ,and indirect bilirubin
Creatinine
Sodium
ALT
Total proteinGlucose
Calcium
Alkaline phosphatase
Chloride
Albumin
Magnesium
Phosphorus
Bicarbonate (carbon dioxide content)
Uric acid
Investigators must document their review of each laboratory  safet y report.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
61
Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Report ing
Definition of AE
AEDefinition
An AE is an y untoward medical occurrence in a patient or clinical study  participant , 
temporally  associated with the use of study  intervention , whether or not considered 
related to the study  intervention .
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease (new or exacerbated) temporall y associated 
with the use of study  intervention .
Events M eeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) 
or other safet y assessments ( eg, ECGs , radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing dise ase); for example:
oThe test result is associated with accompan ying symptoms, and/or
oThe test result requires additional diagnostic testing or medical/surgical 
intervention, and/or
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779239] result leads to a change in stud y dosing (outside of an y protocol -specified 
dose adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y,and/or
oThe t est result is considered to be an AE b y the investigator or s ponsor.
Exacerbation of a chronic or inter mittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition
New condition detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE or SAE unless it is an intentional overdose ta ken with possible 
suicidal/self
-harming intent. Such overdoses should be reported regardless of 
sequelae.
Lack of efficacy  or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AEs or SAEs if they  fulfil the definition of an AE 
or SAE.
Events NOT M eeting the AE Defini tion
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition . Merel y 
repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE. An y abnormal test result that is determined to be an error does not 
require recording as an AE.
The disease/disorder being studied or expected prog ression, signs, or s ymptoms 
(clearly
 defined) of the disease/disorder being studied, unless more severe than 
expected for the participant’s condition
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307])
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
63
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen
Definition of SAE
SAEs must meet both the AE criteria described above and the seriousness criteria listed below .
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life threatening
The term life threatening in the definition of serious refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hos pi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_12332]/or intervention that would not have been appropriate in the ph ysician ’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether hospi[INVESTIGATOR_51956] , the AE 
should be considered serious.
Hospi[INVESTIGATOR_287408] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent disabilit y/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
64f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  lifethreatening or result in death or hospi[INVESTIGATOR_591111]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
interventio nin an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
Recording and Follow -Up of AEs and/or SAEs
AE and SAE Recording
When an AE or SAE occurs , it is the responsibility  of the investigator to review all
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the eCRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the sponsor in lieu of completion of the AE or SAE eCRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y the sponsor . In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copi[INVESTIGATOR_55852] .
The investigator will attempt to establish a diagnosi s of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779240] oneof the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention
and each occurrence of each AE or SAE.
A reasonable possibility of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention
administration will be considered and investigated.
The investigator will also consult t he IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situati ons in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
66The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria use d when determining regulatory  
reporting requirements.
Reporting of SAEs
SAE Reporting
 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE form, sent by [CONTACT_591121] e.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE form within the designated reporting time frames.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
67
Appendix 4: Abbreviations
Term/Abbr eviation Definition
AESI adverse event of special interest
ALT alanine aminotransferase
ANCOV A analysis of covariance 
AST aspartate aminotransferase
BoNT/A botulinum toxin ty pe A 
BUN blood urea nitrogen
CFL crow’ s feet lines
CIOMS Council for International Organizations of Medical Sciences
CMH Cochran -Mantel- Haenszel
CONSOR T Consolidated Standards of Reporting T rials
CFR Code of Federal Regulations
DVD digital versatile disc
ECG electrocardiogram
eCRF electronic case report form
ELISA enzy me-linked immunosorbent assay
EU European Union
FDA Food and Drug Administration
FLO -[ADDRESS_779241]
IB investigator’ s brochure
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IM intramuscular
IND investigational new drug application
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_779242] lower limit of normal value provided b y the laboratory
mITT modified intent- to-treat
PRO patient -reported outcome
RBC red blood cells
SAE serious adverse event
SAP statistical analy sis plan
SI Le Système International d ’Unités (International System of Units)
SoA schedule of activities
S[LOCATION_003]R serious adverse reactions
TCA trichloroacetic acid
TEAE treatment -emergent adverse events
U Units
UFL upper facial lines
ULN upper limit of normal value provided b y the laboratory
US [LOCATION_002]
WBC white blood cells
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
69
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
70
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
71
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
72
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
73
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
74
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
75
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
76
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
77
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
78
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
79
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
80
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
81
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
82
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
83
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
84
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
85
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
86
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
87
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
88
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
89
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
90
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
91
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
92
Appendix 10: Protocol Amendment History
The protocol amendment summary  of changes table for the current amendment is located 
directly  before the table of contents.
Amendment 1 (September  2018)
This amendment is considered to be nonsubstantial  
 
The editorial nature of this amendment is intended to provide 
clarity  of information throughout the document.
Overall Rationale for  the Amendment:
The overall rationale for the changes implemented in the protocol amendment were 
administrative in natur e.
Section Number
and NameDescription of Change Brief Rationale
 
 
   
Throughout Minor editorial revisions Minor , therefore have not been 
summarized
Amendment 2 (November  2018)
This amendment is considered to be nonsubstantial  
 
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
93Overall Rationale for  the Amendment:
The overall rationale for the change implemented in the protocol was administrative in nature.
Section No.
and NameDescription of Change Brief Rationale
Title Page Added Allergan Limited
 Administrative
Amendment 3 ( February 2019)
This amendment is considered to be substantial  
 
 
Section No. and Nam e Description of Change Brief Rationale
1.1 (Synopsis), 3 (Objectives and 
Endpoints), and [IP_ADDRESS] (Primary 
Efficacy Endpoints)Clarified the primary objective and endpoint, added 
secondary objectives, and secondary safety endpointsUpdated per 
recommendation by 
[CONTACT_591122]
1.1 (Synopsis), 3 (Objectives and 
Endpoints), and [IP_ADDRESS] (Secondary  
Efficacy Endpoints)Added new secondary efficacy endpoints New  addition
  
 
 
 
  
 
  
 
1.3 (Schedule of Activities) Modified and added footnotes Improve clarity
  
 
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
94Section No. and Nam e Description of Change Brief Rationale
  
 
   
 
8.3.1 (Time Period and Frequency 
for Collecting Adverse Event and 
Serious Adverse Event 
Information) and 8.3.3 (Follow -up 
of Adverse Events and Serious 
Adverse Events)Added text to clarify that collection of adverse events at
follow -up visits only applies to participants who receive 
study interventionImprove clarity
8.3.1 (Time Period and Frequency 
for Collecting Adverse Event and 
Serious Adverse Event 
Information)Added a statement to clarify the process for collecting 
adve rse events  Improve clarity
 
  
 
  
 
8.3.5 (Pregnancy) and Ap pendix 7 
(subsection of Collection of 
Pregnancy Information )Revised the description of which pregnancy outcomes 
are considered serious adverse events (SAEs)Consistent with the 
new protocol 
template
  
 
 
 
 
   
  
[IP_ADDRESS] (Explor atory Efficacy 
Endpoints) and [IP_ADDRESS] 
(Exploratory Efficacy Analyses)Added a new section (Section [IP_ADDRESS]) and modified 
text in Section [IP_ADDRESS] to provide details about 
exploratory endpoints and analysesUpdated per 
recommendation by 
[CONTACT_591122]
[IP_ADDRESS] (Adverse Events) Revised the duration after which an adverse event will 
not be counted as a treatment -emergent adverse event 
(TEAE)Correction
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
95Section No. and Nam e Description of Change Brief Rationale
[IP_ADDRESS] (Adverse Events) Added a paragraph describing analysis of TEAEs 
related to possible distant spread of toxin (PDSOT) and 
monitoring of PDSOTClarification of 
process
[IP_ADDRESS] (Vital Signs) and [IP_ADDRESS] 
(Electrocardiograms)Modified the description of analyses for clarity Improve clarity
Appendix 1 (subsection of 
Compliance with Protocol )Added tex t to clarify compliance w ith GCP regulations 
and procedures, and training of investigators on study 
requirementsUpdated per 
recommendation by 
[CONTACT_591123] 7 Revised criteria for postmenopausal females who are 
not being considered w omen of childbearing potentialImprove clarity
Appendix 7 (Table 10-2) Added text to include as one of the acceptable birth 
control methods the option of male or female condoms 
without spermicide (in addition to male or female 
condoms with spermicide)Correction
Throughout Minor editorial revisions Minor, therefore 
have not been 
summarized
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
96
References
Beer KR. Comparative evaluation of the s afety  and ef ficacy  of botulinum toxin ty pe A and 
topi[INVESTIGATOR_268328] -to-severe glabellar rh ytids. Dermatol Sur g. 
2006;32:184-1 92.
Blitzer A, Brin MF , Keen MS, Aviv JE. Botulinum toxin for the treatment of hy perfunctional 
lines of the face. Arch Otolary ngol Head Neck Surg. 1993;1 19:1018- 1022.
BOTOX® Cosmetic (onabotulinumtoxinA) for injection [package insert]. Irvine, C A: Allergan, 
Inc; October  2017.
Brin MF , Boodhoo TI, Pogoda JM, James L M, Demos G, Terashima Y, et al. Safet y and 
tolerabili ty of onabotulinumtoxinA  in the treatment of facial lines: A meta -analysis of individual 
patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 
2009;61:961-9 70.e1 -11.
Dmitrienko A, Molenberghs G, Chuang -Stein C, Of fen W. Gatekeepi [INVESTIGATOR_254560]. In: Anal ysis 
of clinical trials using SAS: a practical g uide. Cary , NC : SAS I nstitute; 2005. p. 104-108.
Farage MA, Miller KW , Berardesca E, Maibach HI. Psy chological and Social I mplications of 
Aging Skin: Normal Aging and th e Effects of Cutaneous Disease. In: Farage MA, Miller KW , 
Maibach HI, editors. Textbook of Aging Skin. Springer; [LOCATION_001], [LOCATION_001]: 2010;949 -957.
Ferreira MC, Salles AG, Gimenez R, Soares MFD. Complications with the use of botulinum 
toxin ty pe A in facial  rejuvenation: report of [ADDRESS_779243] Surg. 2004;28:441 -444.
Finn CJ, Cox SE, Earl ML. Social implications of hy perfunctional facial lines. Dermatol Surg. 
2003;29:450- 455.
Garcia A, Fulton JE  Jr. Cosmetic denervation of the muscles of facial expr ession with botulinum 
toxin: A dose-response study . Dermatol Sur g. 1996;22:39- 43.
Khan JA. Aesthetic surgery: Diagnosing and healing the miscues of human facial expression. 
Ophthal Plastic Reconstr Sur g. 2001;17:4 -6.
Koblenzer CS. Psy chologic aspects of aging and the skin. Clin Dermatol. 1996;14:171 -177.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

CONFIDENTIAL Protocol MT10109L -001 AMD 4
MT10109L
97O'Kelly  M, Ratitch B. Clinical trials with missing data: Aguide for practitioner . Statistics in 
Practice. Wiley;
2014.
Wilson EB, Hilferty , MM. The distribution of chi- squared. Proceedings of the Nationa l Academ y 
of Sciences, W ashington. 1931;17:12,684–688.
Approval Date: 30-Sep-2020 22:56:38 (GMT)

Approval Date: 30-Sep-2020 22:56:38 (GMT)
